Updated CAPItello-281 data showed a clinically meaningful benefit in OS when capivasertib was added to abiraterone and ADT in PTEN-deficient mHSPC.
|Videos|October 1, 2021
Dr. Sussman to give malpractice talk at AACU annual meeting
Author(s)Urology Times staff
Ernest Sussman, MD, FACS, explains why all urologists must also be risk managers.
Advertisement
In this video, Ernest Sussman, MD, FACS, offers a preview of his upcoming talk on medical malpractice at the American Association of Clinical Urologists annual meeting on October 16. Sussman is co-founder and treasurer of SCRUBS Risk Retention Group.
Advertisement
Related to this article
Andrea Necchi, MD, discusses how results from the CA017-078 trials compares with other perioperative immunotherapy trials in muscle-invasive bladder cancer.
In TALAPRO-3, talazoparib plus enzalutamide improved rPFS vs placebo plus enzalutamide (HR, 0.48; P < .0001) in HRR-mutated mAPMN/S prostate cancer.
Final phase 3 CA017-078 data show perioperative nivolumab plus GC did not significantly improve pCR (39.1% vs 29.6%) or EFS (HR, 0.94) vs GC alone in MIBC.
Daniel Heng, MD, discusses final LITESPARK-011 results, including sustained PFS benefit with belzutifan plus lenvatinib vs cabozantinib in advanced ccRCC.
In the randomized phase 2 PE-PE trial, median relapse-free survival was 25.4 months with pembrolizumab plus surgery or SABR vs 11.0 months with local therapy alone.
Interim phase 3 data show a 58% reduction in the risk of metastasis or death with the addition of darolutamide to ADT + radiation.
Carlos A. Vargas, MD, discusses updated survival outcomes, safety, and the mechanism of SYNC-T SV-102, an investigational in situ immunotherapy for metastatic prostate cancer.
Advertisement
Advertisement
Trending on Urology Times
1
Adding darolutamide to ADT and radiation improves MFS in very high-risk localized prostate cancer
2
PROTEUS Substudy: Perioperative apalutamide plus ADT improves EFS vs surgery alone
3
Talazoparib/enzalutamide approved for HRR-mutated mAPMN/S prostate cancer
4
Daniel Heng, MD, highlights final LITESPARK-011 results in advanced ccRCC
5